Clinical stage biopharmaceutical company: Principia Biopharma (PRNB)

Principia Biopharma, Inc. (NASDAQ:PRNB) was founded in 2008 and started operations in 2011. It is headquartered in South San Francisco, California, USA, with 57 full-time employees (12/31/2018). It is a clinical-stage biopharmaceutical company dedicated to To provide transformative oral therapy for patients with major medical needs in immunology and oncology.

Principia Biopharma

Principia Biopharma (PRNB):

Principia Biopharma’s proprietary Tailored Covalency ® platform enables it to design and develop potent and selective reversible and irreversible covalent small molecule inhibitors. The company believes that these inhibitors are comparable to injectable biologics while maintaining the convenience of oral administration. Sex.

Principia Biopharma’s strategy is to promote the development of its patented drug candidates. For some programs, it uses cooperation and partnerships as strategic tools to maximize the value of these assets.

Principia Biopharma has produced three new drug candidates from its platform and conducted four clinical programs during the first seven years of the company’s operations. Principia Biopharma retains all rights to the most advanced PRN1008 and PRN1371 projects, and has established a continuous cooperative relationship with Genzyme Corporation, Sanofi and AbbVie .

Principia Biopharma’s BTK franchise :

Principia Biopharma has developed a Bruton’s Tyrosine Kinase (BTK) franchise, which includes two differentiated oral drug candidates: PRN1008 and PRN2246.

Among them, the most advanced drug candidate PRN1008 aims to form a reversible covalent bond with BTK enzyme. This combination confers enhanced selectivity and long-lasting efficacy, which the company believes will be able to treat chronic immune diseases in a long-term and comprehensive manner. The second drug candidate in the company’s BTK franchise is PRN2246, an irreversible covalent BTK inhibitor designed to cross the blood-brain barrier and regulate the function of immune cells in the brain for the treatment of multiple sclerosis And other central nervous system diseases.

Principia Biopharma (PRNB) investment:

Principia Biopharma, Inc. (NASDAQ:PRNB) submitted its IPO prospectus on 8/17/2018 and listed on NASDAQ on 9/14/2018 with an issue price of US$17.00. It issued 6.25 million shares and raised US$10625 million. Joint underwriting by BofA Merrill Lynch / Leerink Partners/ Wells Fargo Securities,

Notify of
Inline Feedbacks
View all Intels

Student loans: The First Marblehead (FMD)-Delisting (1991)

Real estate development company: Forest Forestar Group Inc. (FOR) (1955)